A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)

Trial Profile

A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Calmangafodipir (Primary) ; Acetylcysteine
  • Indications Liver dysfunction; Liver failure
  • Focus Adverse reactions; Proof of concept
  • Acronyms The POP Trial
  • Sponsors PledPharma
  • Most Recent Events

    • 30 Aug 2017 According to a PledPharma media release, 8 out of 24 patients completed their treatment in this trial.
    • 12 Jun 2017 Status changed from not yet recruiting to recruiting
    • 08 Jun 2017 According to a PledPharma media release, this trial is being conducted in collaboration with the University of Edinburgh under the direction of Dr James Dear.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top